Biogen (BIIB) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $3.60
- EPS estimate
- $2.94
- EPS surprise
- +22.49%
- Revenue surprise
- +11.20%
- Revenue
- $2.7B
- Revenue estimate
- $2.5B
- Reported
- Jul 29, 2026
Biogen reported Q2 2026 results on July 29, 2026. Earnings per share came in at $3.60, ahead of the $2.94 estimate by 22.49%. Revenue was $2.7 billion, 11.20% above the $2.5 billion consensus. Compared with Q2 2025, EPS fell about 34% from $5.47, while revenue rose about 4% from $2.6 billion.
The longer record shows earnings moving within a range on flat sales. Annual EPS was $17.69 in 2022, $14.73 in 2023, $16.47 in 2024 and $15.29 in 2025. Annual revenue held between $9.8 billion and $10.1 billion over those four years. The first half of 2026 adds up to $7.17 per share, about 16% less than the same period a year earlier. Q2 2025 set the EPS high in the table at $5.47, and Q4 2025 was the low at $1.99. Over the last 20 quarters, Biogen topped the EPS estimate 18 times. The two misses were Q1 2022, at 16.59% below, and Q4 2023, at 7.35% below.
Biogen reported Q3 between October 20 and November 8 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether revenue holds at the Q2 level.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 29, 2026 | $2.94 | $3.60 | +22.49% | $2.7B | SEC |
| Q1 2026 | Apr 29, 2026 | $3.08 | $3.57 | +15.77% | $2.5B | SEC |
| Q4 2025 | Feb 6, 2026 | $1.63 | $1.99 | +22.45% | $2.3B | SEC |
| Q3 2025 | Oct 30, 2025 | $3.88 | $4.81 | +23.89% | $2.5B | SEC |
| Q2 2025 | Jul 31, 2025 | $3.90 | $5.47 | +40.31% | $2.6B | SEC |
| Q1 2025 | May 1, 2025 | $2.90 | $3.02 | +4.16% | $2.4B | SEC |
| Q4 2024 | Feb 12, 2025 | $3.33 | $3.44 | +3.26% | $2.5B | SEC |
| Q3 2024 | Oct 30, 2024 | $3.77 | $4.08 | +8.15% | $2.5B | SEC |
| Q2 2024 | Aug 1, 2024 | $4.07 | $5.28 | +29.79% | $2.5B | SEC |
| Q1 2024 | Apr 24, 2024 | $3.47 | $3.67 | +5.78% | $2.3B | SEC |
| Q4 2023 | Feb 13, 2024 | $3.18 | $2.95 | −7.35% | $2.4B | SEC |
| Q3 2023 | Nov 8, 2023 | $3.97 | $4.36 | +9.73% | $2.5B | SEC |
| Q2 2023 | Jul 25, 2023 | $3.78 | $4.02 | +6.45% | $2.5B | SEC |
| Q1 2023 | Apr 25, 2023 | $3.28 | $3.40 | +3.72% | $2.5B | SEC |
| Q4 2022 | Feb 15, 2023 | $3.49 | $4.05 | +16.08% | $2.5B | SEC |
| Q3 2022 | Oct 25, 2022 | $4.13 | $4.77 | +15.61% | $2.5B | SEC |
| Q2 2022 | Jul 20, 2022 | $4.06 | $5.25 | +29.30% | $2.6B | SEC |
| Q1 2022 | May 3, 2022 | $4.34 | $3.62 | −16.59% | $2.5B | SEC |
| Q4 2021 | Feb 3, 2022 | $3.38 | $3.39 | +0.38% | $2.7B | SEC |
| Q3 2021 | Oct 20, 2021 | $4.09 | $4.77 | +16.73% | $2.8B | SEC |
Quarterly revenue
Frequently asked questions
When did Biogen (BIIB) last report earnings?
Biogen last reported on Jul 29, 2026, covering fiscal Q2 2026.
Did BIIB beat earnings estimates?
Yes. Biogen reported EPS of $3.60 for Q2 2026 against a $2.94 estimate — a 22.49% beat.
How much revenue did BIIB report last quarter?
Biogen reported $2.7B in revenue for Q2 2026, against a consensus estimate of $2.5B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.